Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis
Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis(360 views) Lanzillo R, Di Somma C, Quarantelli M, Gasperi M, Ventrella G, Prinster A, Vacca G, Orefice G, Colao A, Morra VB
Mult Scler (ISSN: 1352-4585, 1477-0970, 1352-4585linking), 2009 Sep; 15(9): 1402-1406.
Keywords: Case-Control Study, Insulin-Like Growth Factor-Binding Protein-3, Multiple Sclerosis, Relapsing-Remitting, Secondary Progressive, Somatomedin Binding Protein 3, Adult, Article, Clinical Assessment Tool, Controlled Study, Disease Activity, Disease Course, Expanded Disability Status Scale, Female, Human, Major Clinical Study, Multiple Sclerosis Severity Scale, Priority Journal, Protein Blood Level, Secondary Progressive Multiple Sclerosis, Age Factors, Case-Control Studies, Insulin-Like Growth Factor Binding Protein 3, Middle Aged, Chronic Progressive, Severity Of Illness Index, Time Factors, Insulin-Like Growth Factor Binding Protein 3 Blood Physiology, Insulin-Like Growth Factor I Analysis Physiology, Chronic Progressive Blood Physiopathology, Relapsing-Remitting Blood Physiopathology,
Affiliations: *** IBB - CNR ***
Neurology, Hermitage Capodimonte Hospital, Naples, Italy
Department of Neurological Sciences, University 'Federico II', Naples, Italy
SDN Foundation, Naples, Italy
Biostructure and Bioimaging Institute, National Research Council, Naples, Italy
Department of Health Science, University of Molise, Contrada Tappino, Campobasso, Italy
Departments of Molecular and Clinical Endocrinology and Oncology, University 'Federico II', Naples, Italy
References: Roth, G.A., Spada, V., Hamill, K., Bornstein, M.B., Insulin-like growth factor I increases myelination and inhibits demyelination in cultured organotypic nerve tissue (1995) Brain Res Dev Brain Res, 88, pp. 102-10
Mc Morris, F.A., Smith, T.M., De Salvo, S., Furlanetto, R.W., Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development (1986) Proc Natl Acad Sci U S A, 83, pp. 822-826
Mason, J.L., Ye, P., Suzuki, K., D' Ercole, A.J., Matsushima, G.K., Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination (2000) J Neurosci, 20, pp. 5703-5708
Barres, B.A., Hart, I.K., Coles, H.S., Cell death in the oligodendrocyte lineage (1992) J Neurobiol, 23, pp. 1221-1230
Wilczak, N., Schaaf, M., Bredewold, R., Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis (1998) Neurosci Lett, 257, pp. 168-170
Torres-Aleman, I., Barrios, V., Berciano, J., The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis (1998) Neurology, 50, pp. 772-776
Wilczak, N., Ramsaransing, G.S., Mostert, J., Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis (2005) Mult Scler, 11, pp. 13-15
Poljakovic, Z., Zurak, N., Brinar, V., Growth hormone and insulin growth factor-I levels in plasma and cerebrospinal fluid of patients with multiple sclerosis (2006) Clin Neurol Neurosurg, 108, pp. 255-258
Hosback, S., Hardiman, O., Nolan, C.M., Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis (2007) Growth Horm IGF Res, 17, pp. 472-479
Poser, C.M., Paty, D.W., Scheinberg, L., New diagnostic criteria for multiple sclerosis: guidelines for research protocols (1983) Ann Neurol, 13, pp. 227-231
Oscarsson, J., Johannsson, G., Johansson, J.O., Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults (1997) Clin Endocrinol (Oxf), 46, pp. 63-68
Sonntag, W.E., Ramsey, M., Carter, C.S., Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging (2005) Ageing Res Rev, 4, pp. 195-212
Rensink, A.A., Gellekink, H., Otte-Höller, I., Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease (2002) Acta Neuropathol, 104, pp. 525-533
Lovett-Racke, A.E., Bittner, P., Cross, A.H., Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1)and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3) (1998) J Clin Invest, 101, pp. 1797-1804
Rudick, R., Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis? (2003) Mult Scler, 9, pp. 210-212
Yateman, M.E., Claffey, D.C., Cwyfan Hughes, S.C., Cytokines modulate the sensitivity of human fibroblasts to stimulation with insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production (1993) J Endocrinol, 137, pp. 151-159
Besset, V., Le Magueresse-Battistoni, B., Collette, J., Benahmed, M., Tumor necrosis factor alpha stimulates insulin-like growth factor binding protein 3 expression in cultured porcine Sertoli cells (1996) Endocrinology, 137, pp. 296-303
Roth, G. A., Spada, V., Hamill, K., Bornstein, M. B., Insulin-like growth factor I increases myelination and inhibits demyelination in cultured organotypic nerve tissue (1995) Brain Res Dev Brain Res, 88, pp. 102-10
Mc Morris, F. A., Smith, T. M., De Salvo, S., Furlanetto, R. W., Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development (1986) Proc Natl Acad Sci U S A, 83, pp. 822-826
Mason, J. L., Ye, P., Suzuki, K., D' Ercole, A. J., Matsushima, G. K., Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination (2000) J Neurosci, 20, pp. 5703-5708
Barres, B. A., Hart, I. K., Coles, H. S., Cell death in the oligodendrocyte lineage (1992) J Neurobiol, 23, pp. 1221-1230
Poser, C. M., Paty, D. W., Scheinberg, L., New diagnostic criteria for multiple sclerosis: guidelines for research protocols (1983) Ann Neurol, 13, pp. 227-231
Sonntag, W. E., Ramsey, M., Carter, C. S., Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging (2005) Ageing Res Rev, 4, pp. 195-212
Rensink, A. A., Gellekink, H., Otte-H ller, I., Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease (2002) Acta Neuropathol, 104, pp. 525-533
Lovett-Racke, A. E., Bittner, P., Cross, A. H., Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3) (1998) J Clin Invest, 101, pp. 1797-1804
Yateman, M. E., Claffey, D. C., Cwyfan Hughes, S. C., Cytokines modulate the sensitivity of human fibroblasts to stimulation with insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production (1993) J Endocrinol, 137, pp. 151-159
Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis
Background: Insulin-like growth factor (IGF)-I has a role in remyelination, and insulin-like growth factor-binding protein-3 (IGFBP-3) might reduce its bioavailability. A role of IGFBP-3 in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive (PP) MS. Objective: To evaluate serum levels of IGF-I and IGFBP-3 in patients with relapsing-remitting (RR) and secondary progressive (SP) MS and their correlations with disease activity and progression. Methods: Sixty-three (41 RR and 22 SP) 'naive' MS patients and 60 age-matched healthy controls were enrolled. Patients were assessed through clinical [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), number of relapses] and laboratory investigations. IGF-I and IGFBP-3 were measured by ELISA. Results: Levels of IGF-I and IGFBP-3 were similar in the two MS groups. IGFBP-3 levels were higher in patients with MS than in controls (P
Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis
Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis